US envoys say the India-US trade deal is in its "final steps." Here's exactly what's locked in, what's still contested, and the July 24 deadline that matters more than the headlines.
US Ambassador to India Sergio Gor stood up at the US-India Strategic Partnership Forum Leadership Summit this week and said something that's been said, in one form or another, for the better part of 18 months now: the trade deal is in its "final steps." Just 1 percent of the negotiation is left, he told the room. Most of it is done. A few items remain on both sides.
If that sounds familiar, it's because you've heard versions of it before. Back in February, both governments announced a framework with real fanfare. Then a Supreme Court ruling in Washington pulled the rug out from under the whole tariff structure the deal was built on. Talks restarted. A fresh round of ministerial meetings happened in June. Now here we are again, supposedly in the final 1 percent.
So what's actually locked in, what's genuinely still being fought over, and does any of this matter for your portfolio? Let's separate the signal from the diplomatic noise.
Trade talks between India and the US kicked off in February 2025, when Prime Minister Modi and President Trump agreed to negotiate a full Bilateral Trade Agreement. Nearly a year later, on February 6, 2026, both sides announced a framework for an Interim Agreement, essentially a bridge deal meant to lock in early wins while the bigger BTA gets hashed out over the following year or two.
Under that framework, the US agreed to drop its punitive 25 percent tariff on Indian goods immediately and cut its broader reciprocal tariff from 25 percent to 18 percent once the interim deal was formally concluded. In exchange, India offered to eliminate or reduce duties on a long list of US industrial and agricultural products, plus a headline commitment to buy roughly 500 billion dollars of American energy, aircraft, precious metals, technology products and coking coal over five years.
Then, on February 20, the US Supreme Court ruled that the law the administration had been using to impose those reciprocal tariffs, the International Emergency Economic Powers Act, doesn't actually authorize tariffs at all. That single ruling pulled the legal floor out from under the tariff architecture the India framework was resting on. Within hours, the White House pivoted to a different law, Section 122 of the Trade Act, and imposed a temporary 10 percent global tariff surcharge on all countries, India included, for 150 days. That clock runs out on July 24, 2026.
That deadline is precisely why negotiators from both sides have been shuttling between Delhi and Washington nonstop. US Trade Representative Jamieson Greer spent two days in New Delhi in late June meeting Commerce Minister Piyush Goyal. Days before that, Modi and Trump had their first face to face in over a year on the sidelines of the G7 summit in France. The momentum is real. Whether it lands before July 24 is the actual question worth watching, not the "final steps" phrase itself.
Strip away the diplomatic language and a fair amount has genuinely been settled since February, at least on paper.
The US has committed to an 18 percent reciprocal tariff on a broad basket of Indian exports: textiles and apparel, leather and footwear, plastics and rubber, organic chemicals, home decor, and select machinery, down from the 25 percent originally threatened. Once the interim deal is formally signed, that arrangement is also supposed to extend zero or near-zero treatment to generic pharmaceuticals, gems and diamonds, and aircraft parts, three categories that matter enormously to Indian exporters.
On India's side, the government has agreed to eliminate or cut tariffs on US industrial goods and a specific list of agricultural products: dried distillers' grains, red sorghum, tree nuts, fresh fruit, soybean oil, and wine and spirits. India has also floated that 500 billion dollar purchase commitment through 2030, a number that's more aspirational roadmap than binding annual contract at this stage.
Both sides have also agreed, at least in principle, to chip away at non-tariff barriers: easier import licensing for US medical devices and ICT goods, and a review of whether US-developed testing standards can be accepted in the Indian market within six months of the deal taking effect.
Here's where the "1 percent" framing gets a little misleading, because the items still open are the politically hardest ones on the table, not the easiest.
Dairy remains the single biggest sticking point. India has kept dairy out of its tariff-cut list entirely, and Goyal has told Parliament repeatedly that the sector, along with the small farmers and cooperatives behind it, will stay protected. The US has pushed for greater dairy access in nearly every recent round, and hasn't gotten it yet.
Rice, wheat, a wide range of spices, and frozen or preserved vegetables are also explicitly excluded from India's concessions so far. These are sensitive categories tied directly to farmer incomes, and no Indian government wants to be seen opening them up under American pressure right before a politically charged stretch.
On the services side, Indian IT firms are watching the professional mobility conversation closely. Easier visa pathways for skilled workers moving to the US remain unresolved, and it's a topic that directly affects sentiment around IT stocks every time trade headlines break. Pharma access cuts both ways too, India wants faster US regulatory clearances for its generics, not just a friendlier tariff number.
| Area | Status | Key Detail |
|---|---|---|
| US punitive tariff (25%) | Agreed, already removed | Lifted on February 7, 2026 |
| US reciprocal tariff on Indian goods | Agreed, pending final signing | Cut to 18% from 25% for textiles, leather, chemicals and more |
| Pharma, gems and diamonds, aircraft parts | Agreed, conditional | Zero or near-zero tariff once interim deal is signed |
| India's industrial goods tariffs | Agreed | To be eliminated or reduced for US-origin goods |
| Select agri imports (nuts, fruit, soybean oil, wine) | Agreed | India to cut duties |
| Dairy market access | Pending, contested | India holding firm on protecting the sector |
| Rice, wheat, spices, frozen vegetables | Pending, excluded so far | Not part of India's current tariff-cut offer |
| IT services and visa mobility | Pending | No resolution announced yet |
| 500 billion dollar purchase commitment | Agreed in principle | Roadmap through 2030, not a binding annual figure |
Every "final steps" headline eventually circles back to one hard date: July 24, 2026, when the current 10 percent Section 122 tariff surcharge expires. If a signed interim deal isn't in place by then, most US imports are expected to snap back toward pre-April 2025 tariff levels, undoing months of negotiating goodwill overnight. That's the actual pressure point driving Greer's Delhi visits and Goyal's "very close" comments, not diplomatic optimism for its own sake.
It's also worth remembering why the timeline got messy in the first place. Back in February, India had already put a detailed offer on the table, tariff relief across US industrial goods plus a defined basket of farm products like animal feed grains, tree nuts, fruit, soybean oil and wine, and that framework looked close to done before the Supreme Court ruling forced a legal detour. Negotiators aren't starting from scratch now, they're picking up roughly where a fully formed deal left off, which is genuinely why "1 percent" isn't pure spin this time.
For traders and investors, the trade deal isn't an abstract policy story, it shows up directly in sector moves. If you're tracking why IT stocks have been under pressure lately, trade-deal uncertainty around services mobility is part of that broader picture, not just US client spending patterns.
Pharma is the flip side. Generic drugmakers stand to gain the most if the zero-tariff pharma provision actually gets finalized, which is one reason pharma has been building a case as India's new defensive sector even as IT wobbles.
There's a currency and flows angle too. Trade deal clarity tends to support the rupee and steady foreign portfolio flows, worth watching alongside the recent story of FPI money pouring into Indian bonds, since a clean trade resolution removes one more source of rupee volatility heading into August.
None of this is happening in isolation either. Nifty has already been choppy this week on unrelated geopolitical noise, and if you caught the coverage of Nifty closing below 24,000 on Iran-Hormuz tensions, you already know how quickly headline risk from multiple directions can move index levels in a single session. Trade deal news and geopolitical flare-ups are now landing in the same news cycle, and that's exactly the kind of environment where options strategies built for high-volatility weeks tend to earn their keep over a simple buy-and-hold approach.
The framework is real, the tariff cuts on textiles, leather, pharma and gems are genuinely close, and the 500 billion dollar purchase pledge gives both sides a headline number to point to. But dairy, grains, spices and services mobility aren't rounding errors, they're the parts of this negotiation that touch the most politically sensitive constituencies on both sides, and that's exactly why they're still open after 18 months. Watch July 24 more closely than you watch the next "final steps" soundbite. That date will tell you far more about where this deal actually stands.
It's a bridge agreement covering tariff cuts and purchase commitments between India and the US, meant to lock in early wins while a fuller Bilateral Trade Agreement gets negotiated over the next year or two.
US officials say roughly 1 percent of the negotiation remains, but that final 1 percent includes politically sensitive issues like dairy and services mobility, which is why it's taking longer than the phrase suggests.
The US has agreed to an 18 percent reciprocal tariff on major Indian export categories like textiles and leather, down from the earlier 25 percent rate.
Dairy, rice, wheat, a wide range of spices and frozen or preserved vegetables are currently kept out of India's tariff-cut offer to the US.
The current 10 percent Section 122 tariff surcharge expires that day, and without a signed deal, tariffs are expected to move back toward pre-April 2025 levels.
IT and pharma stocks are the most sensitive to trade deal headlines, and clarity on the deal also tends to support the rupee and foreign portfolio flows into Indian markets.